Qiong Wu

Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)

Ping Wang, Ying Cheng, C. Chiu, 2020 .

Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703).

Ying Cheng, Y. Ba, Jianming Xu, 2021, The oncologist.

Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.

Jingnan Shen, Gang Huang, J. Chen, 2018 .

Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.

P. Sun, Yang Yao, Y. Chi, 2016 .

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

F. Du, P. Sun, Yang Yao, 2018, Clinical Cancer Research.

The preliminary efficacy of KN026 (Anti-HER2 BsAb) in advanced gastric and gastroesophageal junction cancer patients with HER2 expression.

Jianming Xu, Yanqiao Zhang, J. Ying, 2021 .

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

Ying Cheng, Jianming Xu, Wei Li, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)

J. Song, Jingxian Shen, Yang Yao, 2019, Annals of Oncology.

Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial.

Ping Wang, Ying Cheng, C. Chiu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.

Ying Cheng, Wei Liu, B. Han, 2016, Chinese clinical oncology.